Cork, M.; Tha?i, D.; Eichenfield, L.; Arkwright, P.; Chen, Z.; Kamal, M.; O’Malley, J.; Bansal, A. Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years With Uncontrolled, Severe Atopic Dermatitis: Results From Patients Who Participated in an Open-Label Phase 2a Study and Then in a Subsequent Phase 3 Open-Label Extension Study. J of Skin 2020, 4, s104.